Climb Bio (CLYM) Operating Expenses (2020 - 2026)

Climb Bio has reported Operating Expenses for 7 years, with the latest figure at $15.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 33.92% year-over-year to $15.2 million; the trailing twelve-month figure through Mar 2026 stood at $60.1 million (down 41.12% YoY), and the FY2025 full-year result was $67.9 million, down 17.24% from the prior year.
• Operating Expenses for Q1 2026 stood at $15.2 million, down from $19.3 million in the prior quarter.
• The five-year high for Operating Expenses was $56.4 million in Q2 2024, with the low at $3.0 million in Q1 2024.
• Historically, Operating Expenses has averaged $14.7 million across 5 years, with a median of $11.7 million in 2024.
• The largest YoY upside for Operating Expenses was 739.62% in 2024 against a maximum downside of 87.18% in 2024.
• Climb Bio's Operating Expenses stood at $9.6 million in 2022, then sank by 46.39% to $5.1 million in 2023, then jumped by 113.02% to $10.9 million in 2024, then surged by 76.85% to $19.3 million in 2025, then slipped by 21.17% to $15.2 million in 2026.
• The last three Operating Expenses figures came in at $15.2 million (Q1 2026), $19.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.